Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells $223,947.99 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 10,287 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $223,947.99. Following the transaction, the chief financial officer owned 93,901 shares of the company’s stock, valued at $2,044,224.77. This trade represents a 9.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Tuesday, January 20th, Timothy Eugene Sullivan sold 2,892 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $19.79, for a total value of $57,232.68.
• On Tuesday, January 13th, Timothy Eugene Sullivan sold 3,856 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total value of $85,564.64.

Apellis Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ APLS opened at $21.76 on Monday. Apellis Pharmaceuticals, Inc. has a 52-week low of $16.10 and a 52-week high of $30.91. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The business has a fifty day moving average of $23.02 and a two-hundred day moving average of $23.59. The stock has a market cap of $2.75 billion, a PE ratio of 70.18 and a beta of 0.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The business had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same quarter in the prior year, the firm earned ($0.46) EPS. The firm’s quarterly revenue was up 133.0% compared to the same quarter last year. As a group, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on APLS. Stifel Nicolaus reduced their target price on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Bank of America raised Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 price target for the company in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 29th. Robert W. Baird increased their target price on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, William Blair reaffirmed an “outperform” rating on shares of Apellis Pharmaceuticals in a report on Monday, December 15th. Twelve equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.53.

Apellis Pharmaceuticals News Roundup

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Parallel Advisors LLC grew its position in shares of Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after buying an additional 855 shares during the period. Jones Financial Companies Lllp grew its holdings in Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after acquiring an additional 1,373 shares during the period. Osaic Holdings Inc. raised its position in shares of Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares during the last quarter. Allworth Financial LP raised its position in shares of Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after acquiring an additional 857 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $64,000. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.